Innovis Asset Management’s Immunic IMUX Stock Holding History

Innovis Asset Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$401K	Buy	27,246 +8,622	+46%	+$166K	0.15%	78
2023 Q2	$467K	Buy	18,624 +10,547	+131%	+$177K	0.17%	77
2023 Q1	$120K	Buy	+8,077	New	+$150K	0.05%	157

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Innovis Asset Management's IMUX Position: Q3 2023 in Review

Innovis Asset Management increased its Immunic (IMUX) stake by 46% in Q3 2023, buying an estimated $166K and bringing the position to 27,246 shares worth $401K. The position accounts for 0.15% of the portfolio, ranked #78.

Innovis Asset Management first reported a position in IMUX in Q1 2023 and has held it in 3 quarters since. The position peaked at $467K in Q2 2023. 53 funds tracked by Wall St. Rank hold IMUX as of Q3 2023.

Innovis Asset Management held 27,246 shares of Immunic worth $401K as of Q3 2023.
Innovis Asset Management bought 8,622 Immunic shares in Q3 2023, an estimated $166K.
Immunic made up 0.15% of Innovis Asset Management's portfolio in Q3 2023, its #78 holding.
Innovis Asset Management first reported a position in Immunic in Q1 2023 and has held it in 3 quarters since.
Innovis Asset Management's Immunic position peaked at $467K in Q2 2023.
53 funds tracked by Wall St. Rank held Immunic as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.